Literature DB >> 19253488

Handling uncertainty of the economic evaluation result: sensitivity analysis.

Supon Limwattananon1.   

Abstract

An economic evaluation of health technology and interventions often comes with uncertainty in the parameters that were used in the model. To determine sensitivity of the result obtained from a reference case analysis, researchers can employ deterministic and probabilistic approaches. This methodological guideline summarizes the principles underlying the sensitivity analysis and recommends that the probabilistic sensitivity analysis is the best method to handle the parameter uncertainty.

Mesh:

Year:  2008        PMID: 19253488

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  18 in total

Review 1.  Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review.

Authors:  Abedin Teimourizad; Aziz Rezapour; Saeed Sadeghian; Masih Tajdini
Journal:  Cost Eff Resour Alloc       Date:  2021-05-21

2.  Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.

Authors:  Sutat Kantito; Surasak Saokaew; Sukit Yamwong; Prin Vathesatogkit; Wisuit Katekao; Piyamitr Sritara; Nathorn Chaiyakunapruk
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

3.  A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.

Authors:  Rosarin Sruamsiri; Piyameth Dilokthornsakul; Chayanin Pratoomsoot; Nathorn Chaiyakunapruk
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

4.  A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.

Authors:  Surachai Kotirum; Bunchai Chongmelaxme; Nathorn Chaiyakunapruk
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

5.  A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

Authors:  Pattara Leelahavarong; Usa Chaikledkaew; Suradej Hongeng; Vijj Kasemsup; Yoel Lubell; Yot Teerawattananon
Journal:  BMC Health Serv Res       Date:  2010-07-16       Impact factor: 2.655

6.  Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.

Authors:  Surasak Saokaew; Wichittra Tassaneeyakul; Ratree Maenthaisong; Nathorn Chaiyakunapruk
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

7.  Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.

Authors:  Naruemon Bamrungsawad; Nilawan Upakdee; Chayanin Pratoomsoot; Rosarin Sruamsiri; Piyameth Dilokthornsakul; Supinya Dechanont; David Bin-Chia Wu; Charungthai Dejthevaporn; Nathorn Chaiyakunapruk
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

8.  Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review.

Authors:  Abdosaleh Jafari; Aziz Rezapour; Marjan Hajahmadi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

9.  Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand.

Authors:  Pattara Leelahavarong; Yot Teerawattananon; Pitsaphun Werayingyong; Chutima Akaleephan; Nakorn Premsri; Chawetsan Namwat; Wiwat Peerapatanapokin; Viroj Tangcharoensathien
Journal:  BMC Public Health       Date:  2011-07-05       Impact factor: 3.295

10.  Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.

Authors:  Rosarin Sruamsiri; Nathorn Chaiyakunapruk; Samart Pakakasama; Somtawin Sirireung; Nintita Sripaiboonkij; Udomsak Bunworasate; Suradej Hongeng
Journal:  BMC Health Serv Res       Date:  2013-02-05       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.